Hyris offers a decentralized DNA-RNA Testing platform to perform PCR analysis. Through the platform it is possible to carry out tests at any place and at any time, at a lower cost than traditional tests, with access to results in real time. The main applications are in the probiotic, botanical, vegetable and commodity sector.

SCENARIO

Hyris was seeking capital to accelerate geographic expansion of existing businesses and to explore new ones, particularly medical diagnostics.

THE ADVISOR’S SUPPORT

With the support of GC, Hyris met several international investors. Among them three VC Funds expressed their interest after several meetings in Hyris’ headquartes and laboratory. Hyris was therefore able to choose Astanor as lead investor and, after the Due Diligence, obtain a hard commitment for an amount higher than initially expected for the round, being able to select the final investor pool.

INVESTORS AND PROCESS

The Series A round has been subscribed by Astanor Ventures and a pool of strategic investors (Indena, NEOS Medica e Pi Campus) adding value beside financial resources.